Esperion Therapeutics, Inc. ESPR R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.esperion.com

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Market & Price

Market Cap

$805.76M

Current Price

$3.13

High / Low (52W)

$4.08 / $0.85

Beta

0.91

Valuation

Stock P/E

inf

Industry PE

23.65

Forward P/E

10.72

PEG Ratio

Book Value

$-1.23

Price to Book

-2.54

P/S

1.93

EV/EBITDA

15.72

Dividend Yield

Profitability & Returns

ROCE

38.63%

ROE

ROA

12.04%

Profit Margin

-1.77%

Op Margin

-8.22%

EPS (Latest Qtr)

$-0.10

EPS (TTM)

$0.00

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.96

Current Ratio

1.53

Debt

$543.81M

Total Assets

$465.89M

Current Assets

$462.57M

Working Capital

$161.76M

Ownership

Promoter Holding

0.68%

Chg in Prom Hold

FII / Inst Holding

69.78%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.19B

Total Revenue (TTM)

$418.24M

EBITDA

$75.89M

Free Cash Flow

$-49.71M

Operating Cash Flow

$-18.19M

Shares Outstanding

257.43M

Gross Margin

57.79%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

74.80%

Profit 5Y

30.10%

Revenue (YoY)

23.20%

Earnings (YoY)

PROS

Healthy ROCE of 38.6%.
Compounding revenue at 74.8% over 5 years.
Profit CAGR of 30.1% over 5 years.

CONS

Trading at a high P/E of inf.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ESPR Esperion Therapeutics, Inc. R2K	3.13	inf	$805.76M	-	38.63%	-	74.80%	30.10%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145.42M	982.00K	981.00K	982.00K	1.84M	212.24M	3.83M	9.64M	7.98M	40.66M	14.41M	18.84M	18.84M	18.98M	24.33M	25.79M	33.97M	137.74M	73.83M	-	-	65.00M	82.39M	87.31M	168.45M	80.10M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.54M	28.54M	41.29M	27.85M	34.57M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33.46M	53.84M	46.02M	140.59M	45.53M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.55M	46.75M	55.98M	55.36M	52.11M
Operating Income	-12.92M	-13.23M	-14.82M	-14.33M	-17.71M	-29.29M	-40.89M	-43.66M	-45.74M	-38.70M	-46.89M	-46.48M	-50.56M	-60.65M	86.93M	-55.30M	-65.77M	-58.96M	-74.45M	129.17M	-80.55M	-95.57M	-82.82M	-32.53M	-55.74M	-42.99M	-52.38M	-41.62M	-48.60M	-37.06M	-27.53M	72.27M	2.58M	-	-	-22.10M	7.09M	-9.96M	85.23M	-6.58M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21.00M	7.79M	-9.26M	86.33M	-5.37M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.43M	20.49M	22.05M	22.64M	19.80M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-40.45M	-12.72M	-31.33M	63.67M	-25.20M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-12.80M	-13.12M	-14.59M	-14.04M	-17.40M	-28.96M	-40.54M	-43.34M	-45.22M	-37.89M	-46.13M	-45.73M	-49.91M	-60.04M	87.38M	-54.22M	-68.38M	-61.95M	-78.25M	124.61M	-85.44M	-104.48M	-90.94M	-43.67M	-69.39M	-56.73M	-66.32M	-55.12M	-61.72M	-49.94M	-41.25M	61.02M	-61.92M	-	-	-40.45M	-12.72M	-31.33M	61.83M	-25.20M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-1.73	-1.71	-	-	3.07	-2.01	-2.52	-2.26	-2.84	4.32	-3.07	-3.89	-3.50	-1.67	-2.62	-0.93	-1.05	-0.81	-0.79	-0.46	-0.37	0.34	-0.33	-	-	-0.21	-0.02	-0.16	0.22	-0.10

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	0	148.36M	227.55M	78.45M	75.47M	116.33M	332.31M	403.13M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	26.97M	43.27M	68.60M	129.22M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	48.51M	73.07M	263.71M	273.91M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	228.01M	228.63M	209.31M	213.64M
Operating Income	-10.16M	-10.20M	-22.76M	-36.22M	-50.04M	-76.15M	-168.98M	-204.59M	-93.10M	-121.40M	-226.73M	-179.50M	-155.56M	54.40M	60.27M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-176.35M	-150.11M	7.57M	63.87M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	56.81M	58.98M	59.25M	84.60M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-233.66M	-209.25M	-51.74M	-20.84M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1.84M
Net Income	-10.82M	-11.74M	-26.09M	-36.38M	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M	-22.68M
Diluted EPS	-	-	-	-	-	-	-	-	-3.59	-5.23	-9.31	-3.52	-2.03	-0.28	-0.11

Compounded Sales Growth

5 Years:	74.80%
1 Year:	23.20%

Compounded Profit Growth

5 Years:	30.10%
1 Year:	-

Stock Price Performance

1 Year:	+268.24%
6 Months:	-15.18%
3 Months:	-6.57%
1 Month:	+63.87%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	7.31M	78.29M	143.28M	295.57M	245.21M	277.83M	143.45M	214.45M	353.26M	-	247.94M	205.80M	343.82M	465.89M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	246.68M	201.06M	338.00M	462.57M
Cash & Equivalents	3.41M	1.57M	6.51M	56.54M	85.04M	77.34M	38.16M	34.47M	36.97M	166.13M	304.96M	-	124.78M	82.25M	144.76M	167.85M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	35.20M	65.62M	94.49M	105.12M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	33.73M	48.49M	80.14M	140.19M
Total Liabilities	-	-	24.70M	4.20M	9.72M	8.31M	16.61M	33.14M	64.33M	194.50M	449.39M	-	571.72M	660.79M	732.54M	767.85M
Current Liabilities	-	-	17.17M	4.20M	5.49M	5.62M	15.59M	33.14M	64.33M	66.08M	94.07M	-	92.31M	156.22M	246.23M	300.81M
Long Term Debt	-	-	7.53M	-	4.23M	2.69M	1.02M	-	-	-	-	-	259.90M	261.60M	237.72M	249.48M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	260.95M	266.17M	297.60M	252.23M
Total Equity	-19.31M	-30.03M	-41.37M	74.09M	133.55M	287.26M	228.60M	244.69M	79.12M	19.95M	-96.13M	-	-323.78M	-454.99M	-388.72M	-301.96M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	76.56M	120.20M	197.85M	247.21M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-38.16M	-47.73M	-131.30M	-148.64M	-70.34M	-85.18M	-	-174.83M	-135.49M	-23.65M	-13.09M
Investing Cash Flow	-	-	-	-	-160.07M	10.12M	-35.85M	140.45M	64.23M	21.36M	-	8.10M	42.50M	-317.00K	0
Financing Cash Flow	-	-	-	-	190.52M	-1.56M	163.46M	10.69M	136.19M	201.72M	-	32.61M	50.46M	86.48M	36.18M
Capital Expenditure	-33.63K	-7.00K	-31.00K	-873.00K	-325.00K	-94.00K	-19.00K	-151.00K	-953.00K	-869.00K	-	-	-	-317.00K	-
Free Cash Flow	-	-	-	-	-38.48M	-47.82M	-131.32M	-148.79M	-71.29M	-86.05M	-	-174.83M	-135.49M	-23.97M	-13.09M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-134.12M	-42.53M	62.51M	23.09M
Share Buybacks	-	-	-	-	-	-	-	0	0	55.00M	0	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	64.3%	62.8%	79.4%	67.9%
Operating Margin %	-	-	-	-	-	-	-	-	-62.8%	-53.3%	-289.0%	-237.8%	-133.7%	16.4%	15.0%
Net Margin %	-	-	-	-	-	-	-	-	-65.5%	-63.1%	-343.0%	-309.6%	-179.9%	-15.6%	-5.6%
ROE %	36.0%	28.4%	-35.2%	-27.2%	-17.3%	-32.8%	-68.2%	-255.1%	-487.0%	149.3%	-	72.2%	46.0%	13.3%	7.5%
ROCE %	-	103.5%	-30.7%	-26.3%	-17.3%	-33.2%	-69.1%	-258.6%	-62.8%	-46.8%	-	-115.3%	-313.8%	55.7%	36.5%

Shareholding Pattern

Insiders

0.68%

Institutions

69.78%

Public Float

70.25%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.93%	17.85M	$55.88M
2	Wasatch Advisors LP	6.13%	15.77M	$49.36M
3	Two Seas Capital Lp	4.43%	11.39M	$35.67M
4	Orbimed Advisors LLC.	4.11%	10.57M	$33.09M
5	Vanguard Capital Management LLC	4.05%	10.43M	$32.66M
6	Two Sigma Investments, LP	3.67%	9.46M	$29.61M
7	Marshall Wace LLP	2.75%	7.08M	$22.15M
8	State Street Corporation	2.74%	7.06M	$22.08M
9	Shaw D.E. & Co., Inc.	2.54%	6.54M	$20.47M
10	Geode Capital Management, LLC	2.31%	5.96M	$18.64M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ESPR

No recent headlines available.

ESPR · Healthcare